Clinical trial

Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency

NCT03008915

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-01-01

PhasePHASE2

Study timeline

Study start (actual)2017-01-01Date precision: month

Registry last updated2021-02-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Alpha-1 Antitrypsin Deficiencyunresolved

Emphysemaunresolved

Chronic Obstructive Pulmonary Diseaseunresolved

Interventions

AspirinDRUG · verified · RxNorm: aspirin

Withdrawal from alpha1 antitrypsin replacement therapyOTHER

Sponsors & collaborators

Columbia Universitylead sponsor

Alpha-1 Foundationcollaborator

Stony Wold-Herbert Fund, Inc.collaborator

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03008915 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.